Crizotinib drugs can be used to treat patients with ROS1-positive lung cancer. But, laboratory tests used to conclude ROS1 status have limitations that can lead to false-negative results. Hence, a secondary analysis with a different test is required to confirm results to treat patients with ROS1-positive lung cancer, reports a new study. This can give reassurance about not missing patients who can benefit from ROS1 directed therapy. The findings of the study are published in the iJournal of General Internal Medicine/i....
Crizotinib drugs can be used to treat patients with ROS1-positive lung cancer. But, laboratory tests used to conclude ROS1 status have limitations that can lead to false-negative results. Hence, a secondary analysis with a different test is required to confirm results to treat patients with ROS1-positive lung cancer, reports a new study. This can give reassurance about not missing patients who can benefit from ROS1 directed therapy. The findings of the study are published in the iJournal of General Internal Medicine/i....